Interventional Oncology & Embolization — Net Sales
Boston Scientific Interventional Oncology & Embolization — Net Sales remained flat by 0.0% to $249.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 16.4%, from $214.00M to $249.00M. Over 2 years (FY 2023 to FY 2025), Interventional Oncology & Embolization — Net Sales shows an upward trend with a 16.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption of the company's oncology-focused medical devices and successful expansion of its interventional product portfolio. A decrease may signal increased competition, pricing pressure, or a slowdown in the adoption of specific minimally invasive oncology treatments.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and technologies specifically design...
Peer comparison
Comparable to specialized oncology or interventional radiology product line revenues reported by diversified medical device manufacturers or specialized medtech firms.
bsx_segment_interventional_oncology_embolization_net_salesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $736.00M | $856.00M | $996.00M |
| YoY Change | — | +16.3% | +16.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's interventional oncology & embolization — net sales?
- Boston Scientific (BSX) reported interventional oncology & embolization — net sales of $249.00M in Q4 2025.
- How has Boston Scientific's interventional oncology & embolization — net sales changed year-over-year?
- Boston Scientific's interventional oncology & embolization — net sales increased by 16.4% year-over-year, from $214.00M to $249.00M.
- What is the long-term trend for Boston Scientific's interventional oncology & embolization — net sales?
- Over 2 years (2023 to 2025), Boston Scientific's interventional oncology & embolization — net sales has grown at a 16.3% compound annual growth rate (CAGR), from $736.00M to $996.00M.
- What does interventional oncology & embolization — net sales mean?
- Total revenue generated from the sale of medical devices used in interventional oncology and embolization procedures.